Skufca J, et al. - Researchers performed a nation-wide retrospective register-based cohort study in Finland to assess the link between HPV2 (a bivalent human papillomavirus vaccine) and selected autoimmune diseases and clinical syndromes. HPV2 was introduced into the Finnish national vaccination programme (NVP) in November 2013 for girls aged 11–13 years with a catch-up for 14–15 year-olds. Findings demonstrated that HPV vaccination in girls 11–15 years of age was not followed by a significantly increased risk for the selected outcomes in these subjects. This study offers valid evidence to counterbalance public scepticism, fears of adverse events and possible opposition to HPV vaccination.